AstraZeneca Drug Extends Survival in Late-Stage Stomach Cancer Study
AstraZeneca’s experimental drug sone-ve helped patients with advanced stomach cancer live longer than analysts had expected, according to late-stage trial data presented Sunday.
Story updates
03:35:10 PM UTC
SquawkNews
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd- and later-line Claudin 18.2-positive advanced gastric cancers…
By Bhanvi SatijaAstraZeneca's LSE:AZN experimental drug sone-ve helped patients with advanced stomach cancer who had received at least two prior treatments to live longer than analysts had expected, according to late-stage trial data presented on Sunday.Patients on the conjugate drug that links an…